Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MT 0169

Next Previous
Drug Profile

MT 0169

Alternative Names: MT-0169; TAK-169

Latest Information Update: 07 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Molecular Templates; Takeda Oncology
  • Class Antineoplastics; Bacterial toxins; Immunoglobulin fragments; Immunotoxins; Recombinant fusion proteins
  • Mechanism of Action Proteasome inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple myeloma; Non-Hodgkin's lymphoma

Most Recent Events

  • 07 May 2025 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV) (Molecular Templates website, May 2025)
  • 28 Jan 2025 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Second-line therapy or greater) in USA (IV, Infusion)
  • 30 Oct 2024 M.D. Anderson Cancer Center withdraws a planned phase-I clinical trial in Acute myeloid leukaemia (Second-line therapy or greater) prior to enrollment initiation due to the PI request (NCT06522373)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top